VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX) in a research report released on Tuesday. The firm issued a sell rating on the stock.

Several other research analysts have also recently issued reports on the company. D. Boral Capital reissued a “buy” rating and issued a $5.00 price target on shares of VolitionRx in a research note on Thursday, February 6th. Benchmark reissued a “hold” rating on shares of VolitionRx in a research note on Friday, November 22nd.

VolitionRx Stock Performance

NYSE:VNRX opened at $0.61 on Tuesday. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.10. The stock has a market cap of $56.60 million, a price-to-earnings ratio of -1.70 and a beta of 1.09. The business has a fifty day moving average of $0.61 and a 200-day moving average of $0.65.

Insider Activity at VolitionRx

In other news, Director Guy Archibald Innes bought 174,764 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This represents a 39.51 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Cameron John Reynolds bought 139,811 shares of the firm’s stock in a transaction that occurred on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the purchase, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 358,266 shares of company stock valued at $204,212 over the last 90 days. 12.80% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

Several hedge funds have recently modified their holdings of the stock. Millennium Management LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $36,000. Lagoda Investment Management L.P. lifted its holdings in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock valued at $4,546,000 after purchasing an additional 1,481,000 shares during the last quarter. Northern Trust Corp lifted its holdings in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock valued at $71,000 after purchasing an additional 28,579 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in shares of VolitionRx during the fourth quarter valued at $29,000. Finally, Geode Capital Management LLC lifted its holdings in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after purchasing an additional 95,900 shares during the last quarter. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.